文献速递胸部肿瘤

B7-H6:小细胞肺癌潜在免疫治疗新靶点

Beyond Programmed Death-Ligand 1: B7-H6 Emerges as a Potential Immunotherapy Target in SCLC.
PubMed 文献 · J Thorac Oncol · 2021-04-08

研究分析108株SCLC细胞系和81例原发肿瘤标本中39种抑制性免疫检查点配体的表达,发现B7-H6蛋白表达高于PD-L1,且高表达与更长无进展生存相关;39种检查点蛋白中有26种在肿瘤中表达丰度高于PD-L1。

要点

  • B7-H6在SCLC细胞系和肿瘤中蛋白表达高于PD-L1(p<0.05)。
  • B7-H6高表达与更长无进展生存相关(p=0.0368)。
  • 39种检查点蛋白中26种在SCLC肿瘤中表达高于PD-L1。

核心结论

  • B7-H6在SCLC中高表达且与无进展生存相关,是PD-L1之外的潜在免疫治疗靶点。

研究设计与样本

  • 分析108株SCLC细胞系和81例原发肿瘤标本的RNA测序数据,评估39种功能验证的抑制性检查点配体表达。
  • 构建含SCLC细胞系和患者标本的组织微阵列,用免疫组化确认蛋白表达,并注释治疗反应和总生存数据。

主要发现

  • B7-H6(NCR3LG1)在细胞系和肿瘤中蛋白表达高于PD-L1(p<0.05)。
  • B7-H6蛋白高表达与更长无进展生存相关(p=0.0368),并与CD45+免疫浸润增加相关。
  • SCLC肿瘤中B7-H6基因表达升高与活化自然杀伤细胞基因签名降低相关。

关键数值与推荐

  • 39种检查点蛋白中26种在SCLC肿瘤中表达丰度高于PD-L1。
  • PD-L1抑制剂联合铂类化疗仅提高总生存2至3个月,且不足20%的SCLC肿瘤PD-L1表达大于1%。

临床怎么用

  • 提示除PD-L1外应评估B7-H6等检查点分子,作为SCLC免疫治疗潜在靶点。
  • B7-H6表达可能与免疫浸润和预后相关,但尚需前瞻性验证。

局限性

  • 研究基于细胞系和肿瘤标本的表达分析,未报告B7-H6靶向治疗的临床干预数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: The programmed death-ligand 1 (PD-L1) immune checkpoint inhibitors, atezolizumab and durvalumab, have received regulatory approval for the first-line treatment of patients with extensive-stage SCLC. Nevertheless, when used in combination with platinum-based chemotherapy, these PD-L1 inhibitors only improve overall survival by 2 to 3 months. This may be due to the observation that less than 20% of SCLC tumors express PD-L1 at greater than 1%. Evaluating the composition and abundance of checkpoint molecules in SCLC may identify molecules beyond PD-L1 that are amenable to therapeutic targeting. METHODS: We analyzed RNA-sequencing data from SCLC cell lines (n = 108) and primary tumor specimens (n = 81) for expression of 39 functionally validated inhibitory checkpoint ligands. Furthermore, we generated tissue microarrays containing SCLC cell lines and patient with SCLC specimens to confirm expression of these molecules by immunohistochemistry. We annotated patient outcomes data, including treatment response and overall survival. RESULTS: The checkpoint protein B7-H6 (NCR3LG1) exhibited increased protein expression relative to PD-L1 in cell lines and tumors (p < 0.05). Higher B7-H6 protein expression correlated with longer progression-free survival (p = 0.0368) and increased total immune infiltrates (CD45+) in patients. Furthermore, increased B7-H6 gene expression in SCLC tumors correlated with a decreased activated natural killer cell gene signature, suggesting a complex interplay between B7-H6 expression and immune signature in SCLC. CONCLUSIONS: We investigated 39 inhibitory checkpoint molecules in SCLC and found that B7-H6 is highly expressed and associated with progression-free survival. In addition, 26 of 39 immune checkpoint proteins in SCLC tumors were more abundantly expressed than PD-L1, indicating an urgent need to investigate additional checkpoint targets for therapy in addition to PD-L1.

来源:J Thorac Oncol,查看原文。版权归原作者所有。

引用

  1. Thomas PL, Groves SM, Zhang YK, et al. Beyond Programmed Death-Ligand 1: B7-H6 Emerges as a Potential Immunotherapy Target in SCLC. J Thorac Oncol. 2021. PMID: 33839362. doi:10.1016/j.jtho.2021.03.011

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。